NASDAQ (SCMP)
$11.65

0.10 (0.87%)

 
Scroll for more

Investors

 

Corporate Governance

Sucampo is committed to maintaining the highest standard of business conduct and corporate governance and to promoting ethical and responsible decision making.

Our Board of Directors has adopted the following corporate governance guidelines to assist the board in its responsibility to oversee management and to serve the best interests of Sucampo and our shareholders.

Our Board Committees are: Audit, Compensation, Nominating and Corporate Goverance. Each director has complete access to officers and employees of the company.

Supporting materials, including our code of conduct and corporate governance guidelines, are below.

 

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

Chairperson
Member
Financial Expert
 
Compensation Committee
Member
Nominating and Corporate Governance Committee
Chair Person
Audit Committee
Member
Nominating and Corporate Governance Committee
Member
Maureen E. O’Connell Financial Expert
Audit Committee
Chair person
Nominating and Corporate Governance Committee
Member
Compensation Committee
Member
Nominating and Corporate Governance Committee
Member
Audit Committee
Member
Compensation Committee
Member
Audit Committee
Member
Compensation Committee
Chair Person
 
 

For investor inquiries please contact:

Silvia Taylor

Senior Vice President, Investor Relations and Corporate Affairs

Email: investor@sucampo.com

Phone: +1-240-223-3718

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.